At the news
? BULLISHIMPACT 7/10 8-K filed Feb 24, 2026 at 09:10 ET
Oncolytics Biotech announced it will prioritize registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC) based on promising data from Cohort 4 of its GOBLET study. The company has concluded enrollment in the GOBLET trial and plans to meet with the FDA in mid-April to finalize the design of a single-arm SCAC registrational study it believes can be completed with fewer than 100 patients. Enrollment in the pancreatic cancer (PDAC) arm has been stopped at ~20 patients per arm to conserve capital.
- Company will focus on registrational/enabling studies in SCAC and CRC based on GOBLET Cohort 4 data
- GOBLET study enrollment concluded; no further patients will be enrolled in PDAC cohorts
- Plans to meet FDA in mid-April to align on single-arm SCAC registrational study design
- Believes trial of fewer than 100 patients may be sufficient for FDA approval in SCAC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access